Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.

ABSTRACT:

Context

Somapacitan is a long-acting growth hormone (GH) in development for once-weekly treatment of GH deficiency (GHD). Optimal monitoring of insulin-like growth factor-I (IGF-I) levels must account for weekly IGF-I fluctuations following somapacitan administration.

Objective

To develop and assess the reliability of linear models for predicting mean and peak IGF-I levels from samples taken on different days after dosing.

Design

A pharmacokinetic/pharmacodynamic model was used to simulate IGF-I data in adults and children following weekly somapacitan treatment of GHD.

Setting and patients

39 200 IGF-I profiles were simulated with reference to data from 26 adults and 23 children with GHD.

Intervention(s)

The simulated dose range was 0.02 to 0.12 mg/kg fo

SUBMITTER: Juul Kildemoes R 

PROVIDER: S-EPMC7823237 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature